Telemedicine and Mobile Health Innovations Amid Increasing Regulatory Oversight

by Pepper Hamilton LLP
Contact

Reprinted with Permission. © 2014 Thomson Reuters.

The growing mobile health market is rapidly transforming health care delivery. More than 80 percent of physicians use mobile technology to provide patient care, and more than 25 percent of commercially insured patients use mobile applications to manage their health.1

Technological advancements, the expansion of access to health care under the Patient Protection and Affordable Care Act, Pub. L. No. 111-148, the emphasis on cost-effective quality care and the proliferation of mobile medical applications have pushed telemedicine to the new frontier of health care delivery.

Over the past 50 years, the scope of telemedicine practices has expanded to meet demands for immediate care in both remote and metropolitan regions. Mobile health, a form of telemedicine using wireless devices and cell phone technologies, has also evolved. By the end of this year, experts expect 2 billion smartphones, tablets and other portable devices globally, each of which can potentially provide individuals access to health care information from anywhere at any time.2

In light of the seemingly limitless opportunities in telemedicine, health care providers, consumers and entrepreneurs must navigate the many risks that come with reliance on these new technologies and comply with an increasing number of regulations.

Understanding Telemedicine and Mobile Health

Telemedicine involves direct patient care and is a subcategory of telehealth, a broader concept that includes telecommunications technologies, or mobile medical applications, to remotely support health care, health-related education, public health and health administration.3 Generally, telemedicine involves:

  • geographic separation between two or more participants or entities engaged in health care
  • the use of telecommunications technology to gather, store and disseminate health-related information
  • the use of interactive technologies to assess, diagnose and treat medical conditions.

Mobile health is a medium through which telemedicine is practiced. It allows for increased provider and patient mobility, as well as greater delivery of clinical care via consumer-grade hardware, such as smartphones and tablets.4

Recent Telemedicine and Mobile Health Trends

The resurgence of telemedicine began in 2011, when the U.S. Centers for Medicare & Medicaid Services issued a much-awaited final rule permitting a more flexible process for credentialing and privileging practitioners who provide these services. The trend escalated in 2013, when federal and state legislation and major insurers expanded the types of reimbursable telemedicine services. In 2014, the trend continues with the Federation of State Medical Boards' adoption of a model policy intended to provide guidance to state medical boards for regulating the use of telemedicine technologies.5

Increasingly, there are more arrangements for distant-site specialists to provide tele-ICU (intensive care unit), tele-stroke and other telemedicine services; partnerships between insurers and integrated health care delivery systems to provide patients in rural communities access to specialists through telemedicine programs; and development of mobile technology for patient monitoring, patient engagement and virtual clinical encounters.

Within the mobile health industry, pharmacy management continues to be the most common use of mobile technologies. Growth will most likely continue as data analytics vendors launch hosting platforms that make it easier for mobile application developers to comply with federal privacy and security requirements in the health care arena.

Navigating Legal Issues in Telemedicine and Mobile Health

As more health care entities use telemedicine, more consumers rely on these and mobile health services, and more entrepreneurs develop telemedicine technologies, oversight and scrutiny by state medical boards and federal and state regulatory agencies also continue to increase.

Providers, consumers and entrepreneurs must be mindful of the following legal issues to ensure their telemedicine and mobile health services are compliant with federal and state requirements, and appropriately protect patient safety and privacy.

Provider Considerations

Reimbursement

Reimbursement continues to be a significant barrier to telemedicine. Medicare reimbursement for telemedicine services is limited. Generally, it requires face-to-face contact between a patient and provider, with exceptions for certain telemedicine services provided at eligible facilities located in rural, non-metropolitan areas with health care professional shortages.

Medicaid reimbursement varies from state to state, and only about 20 states have enacted statutes that recognize or require commercial insurers to reimburse for certain telemedicine services.

Providers should be aware of the reimbursement requirements and restrictions that may affect their billing practices, know which telemedicine services will be reimbursed and only submit compliant claims to avoid liability for fraud and abuse or false claims.

Fraud and Abuse

Telemedicine services often involve business arrangements between unrelated health care entities and may include the lease of equipment or the use of a product owned in part by physicians. Such business arrangements must be structured in a manner that does not implicate federal fraud and abuse laws, including the Anti-Kickback Statute and the Stark Law.

Under the Anti-Kickback Statute, it is a crime to knowingly offer, pay, solicit or receive any remuneration to induce referrals of items or services reimbursable by a federal health care program.6 Arrangements meeting certain requirements that are set forth in regulatory safe harbors do not implicate the statute.

The Stark Law prohibits physicians from referring Medicare patients for designated health services to an entity with which the physician has a financial relationship.7 It includes exceptions that apply to ownership interests and compensation arrangements involving physicians.

Advisory opinions issued by the U.S. Department of Health and Human Services' Office of Inspector General addressing telemedicine-related fraud issues provide additional guidance for providers and entrepreneurs when structuring telemedicine arrangements.8

Medical Staff Bylaws

Health care organizations that provide telemedicine services must review and revise their medical staff bylaws and credentialing and privileging policies to make sure they cover telemedicine practitioners and practices. These documents must include criteria for granting privileges to distant-site practitioners and a procedure for applying the criteria to those practitioners.9 They should also address what category of the medical staff distant-site telemedicine practitioners will join, the level of involvement they may have in medical staff committees and the procedural rights they will enjoy.

Credentialing and Privileging

Regardless of telemedicine advancements, health care organizations remain liable for the care provided to their patients. Under CMS' final rule, effective July 5, 2011, health care organizations may rely on the credentialing and privileging decisions of distant-site hospitals or information provided by other telemedicine entities when determining privileges for practitioners who provide telemedicine services as long as certain conditions are met, including a compliant written agreement.10

To mitigate possible negligent credentialing claims and associated risks, when entering into written agreements with distant sites, health care organizations must know who will be providing care to patients, confirm that any written agreement they sign reflects current legal requirements and establish specific responsibilities of distant-site hospitals and telemedicine entities. They must also ensure that written agreements include adequate representations, warranties and indemnifications regarding the quality of services provided by the distant site and any entity with which it subcontracts.

Distant sites, in turn, must have processes to assess the quality of their practitioners. While distant-site, Medicare-participating hospitals are highly regulated, distant-site telemedicine entities are not. Therefore, relationships with such entities require greater scrutiny to assure the quality of the telemedicine services being provided and the qualifications of the practitioners providing them.

Peer Review

The expansion and increased reliance on telemedicine means that health care organizations and telemedicine entities must develop policies and procedures for monitoring telemedicine practitioners and sharing internal review information. While information needed to make accurate credentialing and privileging decisions should be regularly shared, it must be done in a manner that maintains and protects the privacy of peer review and patient information.

At a minimum, this shared information must include adverse events that result from a practitioner's telemedicine services and complaints a health care organization receives about a practitioner.11 Health care organizations should determine what additional information, if any, to collect, how to use and act on this information and what information to share so that all peer-review privileges under state law are preserved.

Compliance with State Requirements

Most states continue to require physicians engaging in telemedicine to be licensed in the state where the patient is located, with limited exceptions for consultations. For telemedicine and mobile health services, health care organizations and providers need expert legal guidance to navigate individual state requirements, including licensure, consent and patient notice and practice of medicine issues, and the possible exceptions to such requirements.

Consumer and Patient Consideration

Patient Privacy

Entrepreneurs are continuing to develop mobile medical applications for virtual physician-patient and clinical interactions across the continuum of care. These include payment portals and applications dedicated to medication management, fitness and consumer health.

Prior to relying on any telemedicine technology to collect and transfer patients' protected health information, health care entities should ensure that they have secure communication channels; implement entity- and technology-specific business associate and other confidentiality and privacy agreements; educate administrators and users regarding the appropriate use of telemedicine technologies; and understand how and what patient information is being collected, transmitted, used and stored.

When information is shared between unrelated entities, all disclosures must comply with federal and state privacy and security laws, including the Health Insurance Portability and Accountability Act, or HIPAA, Pub. L. 104-191, and the Health Information Technology for Economic and Clinical Health Act, Pub. L. No. 111-5, and guidance by the Federal Trade Commission.

As a result of modifications to federal privacy and security laws in 2013, all subcontractors having access to protected health information (no matter how far down the chain) must now comply with the full spectrum of requirements applicable to business associates.12

With the development of mobile applications, the Federal Trade Commission and U.S. Department of Health and Human Services are recognizing that health data is moving beyond the traditional medical-provider context and falling outside the scope of federal and state privacy laws as more consumers are managing and controlling their own health data.

HHS has announced that its Office of Inspector General intends to review the security of portable devices used in hospitals that access protected health information as part of its HIPAA compliance audits.13 Emphasis is being placed on transparency and clear notice to consumers about how their health data is being collected, stored, and shared when provided through mobile applications.14

Technology and Vendor Considerations

Regulatory Overlap

Developers and manufacturers of mobile health applications and devices that support telemedicine services must comply with multiple, and often conflicting, privacy and security regulations promulgated by various federal agencies:

  • The Food and Drug Administration establishes regulations regarding the hardware and software, including the safety and effectiveness, of telemedicine devices and mobile medical applications.
  • The Federal Communications Commission establishes regulations regarding interstate and international communications by airwaves, including wireless technology issues and problems with connectivity, as well as technical regulations for transmitters and other equipment.
  • The Federal Trade Commission establishes regulations regarding disclosures about the collection and use of consumer data to avoid false, misleading and deceptive trade practices and provides a privacy-by-design framework for protecting mobile privacy. The FTC is currently examining health care competition, including regulatory barriers that may prevent telemedicine across state lines.
  • The Office of National Coordinator for Health Information Technology, or ONC, establishes regulations to adopt standards and certification criteria for health information technology.

Inter-agency Collaboration

Given the potentials for overlap, in 2012, through the FDA Safety and Innovation Act, Congress required the Food and Drug Administration to consult with the FCC and ONC to develop a report with recommendations for a risk-based regulatory framework pertaining to health IT that avoids regulatory duplication.

On April 3, 2014, HHS released the draft report prepared by the FDA, FCC and ONC,15 which identified three categories of health IT, based on function and level of risk to patient safety, rather than the platform on which it operates:

  • Administrative health IT functions, such as billing and scheduling.
  • Health management health IT functions, such as health information and data exchange, electronic access to clinical results, and medication management.
  • Medical device health IT functions, such as computer aided detection software and robotic surgical planning and control.

The agencies concluded that the administrative and health management functions posed little risk to patient safety and required either no or limited additional oversight. However, because of their recognized risks, medical device health IT functions would remain under FDA oversight.

This proposed functional categorization emphasizes that the safety of health IT relies not only on how it is designed and developed, but also on how it is customized, implemented, integrated and used by clinicians, patients and vendors.

FDA Guidance

Recently, the FDA has been active in regulating mobile health, extending its jurisdiction into health care information technology and redefining medical devices to include software applications, including mobile medical applications. In 2013 it issued guidance for developers and manufacturers on what mobile medical applications qualify as a medical device and further guidance on cybersecurity concerns in this market.

On Sept. 25, 2013, the FDA issued a final guidance on mobile medical applications to provide clarity for developers and manufacturers regarding regulatory oversight.16 According to the agency, whether a mobile application constitutes a medical device that is subject to FDA regulation depends on its intended use.17 Specifically, the FDA guidance separates mobile applications into three categories:

  • Mobile applications that are considered medical devices and subject to FDA regulations (e.g., applications that are intended to be used as an accessory to a medical device to control the device or display patient-specific data, that transform the mobile platform into a medical device with attachments or sensors, or that perform patient-specific analysis and assist with diagnosis or treatment recommendations).
  • Mobile applications that may be considered medical devices, but which the FDA does not currently intend to regulate (e.g., applications that supplement clinical care by helping patients manage their health, that help patients document or communicate their medical information to providers, or that perform simple calculations used in clinical practice).
  • Mobile applications that could be used in a health care environment, but are not considered medical devices (e.g., electronic copies of reference materials, educational tools for medical training, applications used for general patient education, and applications that automate general office operations in a health care setting).

The regulatory overlap surrounding mobile medical applications is complex and likely to change as federal agencies continue to interact. Even if a mobile application is not currently subject to FDA regulation, the application may be subject to other federal and state agency regulations.

On June 14, 2013, the FDA issued draft guidance on medical device cybersecurity that supplements existing policies18 and addresses issues that manufacturers should consider when designing medical devices to effectively mitigate these risks.19 Such risks include the intentional or unintentional compromise of a device or its stored data. According to the agency, medical devices capable of connecting to another medical device, the Internet or other network, or portable media are more vulnerable to cybersecurity threats than those that are not connected.

The FDA recommends manufacturers develop security controls to maintain the confidentiality, integrity, and availability of information stored in medical devices. Additionally, cybersecurity issues and risks should be addressed and analyzed in the design phase, both for efficiency in the FDA approval process and greater effectiveness in managing a device's security.

Conclusion

Increased use of mobile medical technology comes with heightened regulations to mitigate the privacy and security risks of the interconnected health care environment. The absence of comprehensive national privacy and security legislation has driven regulatory agencies to step in.

To navigate the multifaceted legal complexities of telemedicine and mobile health, health care companies should appoint an interdisciplinary committee to monitor regulatory guidance, assess common compliance principles across regulatory agencies, document compliance with privacy and security criteria, perform regular risk analysis for privacy and security issues and develop incident response programs.

Endnotes

1 Press Release, Healthcare Info. & Mgmt. Sys. Soc'y Analytics, HIMSS Analytics 2013 Mobile Technology Survey Examines mHealth Landscape (Feb. 26, 2014), http://bit.ly/1uBlbFa; Matt Mattox, 10 Key Statistics about mHealth (Jan. 15, 2013), http://bit.ly/1lwaaFr.

2 IMS Inst. for Healthcare Informatics, Patient Apps for Improved Healthcare: From Novelty to Mainstream (October 2013), available at http:// bit.ly/1lwajsG.

3 The Centers for Medicare and Medicaid Services defines telemedicine as “the provision of clinical services to patients by practitioners from a distance via electronic communications.” 76 Fed. Reg. 25,553 (May 5, 2011).

4 Am. Telemedicine Ass'n, Telemedicine Frequently Asked Questions, What is mHealth?, http://bit.ly/1pdl6Gj.

5 The Federation of State Medical Boards defines telemedicine technologies as “technologies and devices enabling secure electronic communications and information exchange between a licensee in one location and a patient in another location with or without an intervening health care provider.” Fed'n of State Med. Bds., State Medical Boards' Appropriate Regulation of Telemedicine (SMART) Workgroup, Model Policy for the Appropriate Use of Telemedicine Technologies in the Practice of Medicine (Apr. 26, 2014), available at http://bit.ly/1ibJadE.

6 42 U.S.C. § 1320a-7b.

7 42 U.S.C. § 1395nn.

8 See generally U.S. Dep't of Health & Human Servs., Office of Inspector Gen., Advisory Opinions, available at http://1.usa.gov/1nNDB4B.

9 42 C.F.R. §§ 482.12(a)(8), (a)(9); see also CMS State Operations Manual, Appendix A-Survey Protocol, Regulations and Interpretive Guidelines for Hospitals, Interpretive Guidelines for §§ 482.12(a)(8) & (a)(9).

10 42 C.F.R §§ 482.12(a)(8), (a)(9).

11 42 C.F.R. §§ 482.22(a)(3)(iv), (a)(4)(iv).

12 45 C.F.R. §§ 160.103; see also Rebekah Monson, Sharon Klein & Henry Fader, The Omnibus Final HIPAA Rule Is Here, Pepper Hamilton LLP Health Care Law Alert (Jan. 24, 2013), available at http://bit.ly/1nimm9Q.

13 U.S. Dep't of Health & Human Servs., Office of Inspector Gen., Work Plan for Fiscal Year 2014, at 26, available at http://1.usa.gov/1kL18OM.

14 Allison Grande, Health Apps Need More Privacy Safeguards, FTC Panel Says, Law360 (May 7, 2014), available at http://bit.ly/UJ01KL; see also Sharon R. Klein & Jeffrey L. Vagle, FTC Recommends Framework for Mobile Privacy, Pepper Hamilton LLP Client Alert (Feb. 25, 2013), available at http:// bit.ly/1l0TPYi.

15 Press Release, U.S. Dep't of Health & Human Servs., Proposed health IT strategy aims to promote innovation, protect patients, and avoid regulatory duplication (Apr. 3, 2014); see also U.S. Food & Drug Admin., Fed. Commc'ns Comm'n & Office of Nat'l Coordinator for Health Info. Tech., FDASIA Health IT Report: Proposed Strategy and Recommendations for a Risk-Based Framework (April 2014), available at http://1.usa.gov/1oBNDZZ.

16 U.S. Food & Drug Admin., Mobile Medical Applications: Guidance for Industry and Food and Drug Administration Staff (Sept. 25, 2013), available at http://1.usa.gov/1lBzw3p. The FDA guidance defines a “mobile application” as a software application that can be run on a mobile platform, or a Web-based software application that is tailored to a mobile platform but is executed on a server, and a “mobile medical application” as a mobile application that meets the statutory definition of a “device” and either is intended to be used as an accessory to a regulated medical device, or to transform a mobile platform into a medical device.

17 Sharon R. Klein & Dayna C. Nicholson, When Is an iPad More Than an iPad? When It Is an FDA Regulated Medical Device, Pepper Hamilton LLP Client Alert (Mar. 7, 2014), available at http://bit.ly/1uBneZU.

18 See U.S. Food & Drug Admin., Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005), available at http://1.usa.gov/1lBzGaK; U.S. Food & Drug Admin., Guidance to Industry: Cybersecurity for Networked Medical Devices Containing Off-the-Shelf (COTS) Software (Jan. 14, 2005), available at http://1.usa.gov/1pFTVYd.

19 See U.S. Food & Drug Admin., Content of Premarket Submissions for Management of Cybersecurity in Medical Devices (June 14, 2013), available at http://1.usa.gov/T7ls6K; see also Sharon R. Klein & Odia Kagan, Unhack My Heart: FDA Issues Guidance to Mitigate Cybersecurity Threats in Medical Devices, Pepper Hamilton LLP Client Alert (June 24, 2013), available at http://bit.ly/1iarYpf.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Pepper Hamilton LLP | Attorney Advertising

Written by:

Pepper Hamilton LLP
Contact
more
less

Pepper Hamilton LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.